CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.
|Indication||Hepatocellular Carcinoma (HCC)|
|Funding Request||For the treatment of adult patients with advanced (not amenable to curative therapy or local therapeutic measures) or metastatic hepatocellular carcinoma who are intolerant to or have progressed on sorafenib therapy|
|Pre Noc Submission||No|
|NOC Date||March 23, 2018|
|Manufacturer||Bristol-Myers Squibb Canada|
|Sponsor||Bristol-Myers Squibb Canada|
|Submission Date||May 8, 2018|
|Submission Deemed Complete||May 15, 2018|
|Prioritization Requested||Not Requested|
|Stakeholder Input Deadline ‡||May 23, 2018|
|Check-point meeting||July 10, 2018|
|pERC Meeting||September 20, 2018|
|Initial Recommendation Issued||October 4, 2018|
|Feedback Deadline ‡||October 19, 2018|
|pERC Reconsideration Meeting||November 15, 2018|
|Final Recommendation Issued||November 29, 2018|
|Notification to Implement Issued||December 14, 2018|
|Therapeutic Area||Metastatic Hepatocellular Carcinoma (HCC)|
|Recommendation Type||Do not reimburse|
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.